Breast cancer medicine Perjeta continues to impress clinical researchers with latest results from the NeoSphere study showing its efficacy in treating HER2+ early breast cancer.
An Otago researcher who spent 10 years based at the Translational Genomics Research Institute in Arizona, USA, is now bringing her knowledge of treating triple negative breast cancer (TNBC) patients to New Zealand.
Recent research carried out in the Waikato region has found that breast cancer patients who discontinue their endocrine therapy are more likely to have their breast cancer return or die from it than those who complete their treatment.
Blenheim woman, Tracey Eising, shares with us a moving and poignant moment of her life on the breast cancer journey. Tracey was first diagnosed with Stage 3, ER+ breast cancer in 2004 at age 37 and received a lumpectomy, chemotherapy and radiation. Five years later, Tracey was diagnosed with metastatic breast cancer - the cancer had spread to her liver, lungs and bones. Here, the mum of four children, shares what she describes as a 'Mother's Cry' moment:
BCAC’s meeting with the new Minister of Health, Dr Jonathan Coleman earlier this week, to discuss issues affecting breast cancer patients, has led to the Minister proposing to develop and implement a Breast Care Work Programme.
BCAC Chair, Libby Burgess says the Minister was receptive to many of the issues raised and he has directed Ministry staff to meet quarterly with BCAC to develop a high level Breast Care Work Programme.
A recently published paper by a New Zealand surgeon comparing breast cancer survival rates in Australia and New Zealand reveals lower overall survival rates at five years for New Zealand women, with Māori and Pacific survival found to be significantly worse than other ethnicities.